QT-prolongation in Psychiatric Hospitals

N/ACompletedNCT02043925

KU Leuven152 enrolled

Overview

Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug. An ECG is taken before the administration of the new drug and a week after starting the new drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation and blood concentrations of potassium and creatinine are documented.

Study Type

OBSERVATIONAL

Enrollment

152

Conditions

QT-prolongation

Interventions

drugs linked with QT-prolongationDRUG

all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * inpatient in one of the 6 participating psychiatric hospitals * QT-prolonging drug in the medication profile and the doctor prescribes another QT-prolonging drug Exclusion Criteria: * age \< 18 year

Locations (1)

Psychiatrisch Centrum Sint-Jan

Eeklo, Belgium

Outcomes

Primary Outcomes

change in QTc-interval (corrected for heart rate)

Time frame: before and one week after the start of a QT-prolonging drug

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.